Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002214 · ClinicalTrials.gov registry record · Phase 1

Phase I Trial of S-1153 in Patients With HIV Infection

A Phase 1 study of HIV Infections, sponsored by Lexigen Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT00002214: Completed Phase 1 study of HIV Infections, sponsored by Lexigen Pharmaceuticals.

NCT00002214 is a Phase 1 study of HIV Infections that has completed, run by Lexigen Pharmaceuticals. The registered enrollment target is 40 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002214, a Phase 1 study of HIV Infections, has completed, sponsored by Lexigen Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

To assess the toxicity profile and determine the maximum tolerated dose (MTD), if possible, of S-1153 administered orally 3 times daily for 14 days. To investigate the clinical pharmacokinetic parameters for S-1153. To assess anti-HIV activity associated with S-1153 administration through evaluation of CD4 and viral load measurements.

Conditions Studied

HIV Infections

Interventions

  • DRUG Capravirine

Study Locations (1)

Massachusetts

  • Beth Israel Deaconess Med Ctr - Boston

Trial Details

FieldValue
Enrollment Target 40 participants
Phase Phase 1

Sponsor

Lexigen Pharmaceuticals

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002214

The ClinicalTrials.gov registry entry for NCT00002214 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (91% lower). The listed sponsor is Lexigen Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Capravirine is the first listed.

NCT00002214 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00002214 about?

NCT00002214 is a clinical study titled "Phase I Trial of S-1153 in Patients With HIV Infection". To assess the toxicity profile and determine the maximum tolerated dose (MTD), if possible, of S-1153 administered orally 3 times daily for 14 days. To investigate the clinical pharmacokinetic parameters for S-1153. To assess anti-HIV activity associated with S-1153 administration through evaluation...

What is the current status of trial NCT00002214?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants.

What conditions does trial NCT00002214 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002214?

The interventions under investigation include: Capravirine (DRUG).

Who is sponsoring clinical trial NCT00002214?

This trial is sponsored by Lexigen Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002214 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.